Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround
Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook
Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.
Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Matt Scalo - SVP, IR Sam Raha - President & CEO Scott Leffler - CFO Mark Verratti - COO Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners David Westenberg - Piper Sandler Tejas Sawant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper - Raymond James Tycho Peterson - Jefferies Lu Li - UBS Operator Welcome to the Myriad Genetics First Quarter 2025 Financial Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Matt Scalo, Senior Vice President of Investor Relations.
Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad Genetics (MYGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.01 per share a year ago.
Myriad Genetics: Significantly Undervalued With Profitability In Sight
Initiate Buy on Myriad Genetics, trading near multi-year lows with potential for significant growth driven by new offerings and stable core franchises. Strong financials with $158 million in liquidity, improving margins, and a path to profitability by 2025; 2024 revenue grew 11% YoY to $838 million. Key growth drivers include GeneSight, MyRisk, Prolaris, Precise MRD, and FirstGene; significant market opportunities in psychiatric PGx, hereditary cancer, prostate prognostics, MRD, and prenatal genetics.
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
Medical Equipment Stock Jumps on Upgrade
Medical equipment stock Myriad Genetics Inc (NASDAQ:MYGN) was last seen up 9.8% at $11.25, after an upgrade from Piper Sandler to "overweight" from "neutral," with a price-target hike to $12.50 from $11.50.
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc's UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics' GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect in the first half of 2025.
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.
